Krka reports 8% sales growth as Eastern Europe drives first-quarter gains

Krka reported first-quarter sales growth of 8%, with EBITDA up 20% year over year to €175.7 million and EBITDA margin expanding 310 bps to 31.0%. Gross margin improved to 60.4% and prescription drug sales rose 10%, though net profit fell 21% to €121 million due to FX base effects from last year's Russian ruble gain. The company reaffirmed its full-year 2026 guidance and bought back €13.6 million of shares in the quarter.

Analysis

The key read-through is that the business is not just growing, it is improving mix and monetizing pricing power in geographies where competitors typically face the most regulatory and FX friction. That combination usually supports multiple expansion because it signals the firm can defend margin even if top-line growth slows, especially when prescription mix is rising faster than OTC. The buyback adds a second layer of support: at current profitability, capital returns can absorb a meaningful share of free cash flow, which tends to dampen downside in lower-liquidity European healthcare names.

The more important second-order effect is competitive. Stronger performance in Eastern Europe and the prescription channel implies the company is still taking share from smaller regional generics players that are more exposed to working-capital stress and less able to pass through input costs. If this persists for 2-3 quarters, expect distribution partners and hospitals to consolidate around the few suppliers that can combine reliable supply with stable pricing, which is structurally favorable for incumbents with scale and balance-sheet capacity.

The apparent profit decline is likely the market’s main misread, and it should fade as a headline over the next 1-2 quarters if FX base effects normalize. The real risk is not the prior-year comparison but whether the current margin profile is sustainable if ruble volatility reverses or if government pricing pressure intensifies in core markets. Another tail risk is capital allocation creep: continuing buybacks while also funding expansion can look shareholder-friendly until cash conversion weakens; that inflection would matter over a 6-12 month horizon.

The contrarian view is that the market may still be underestimating how much of this is a quality story rather than a cyclical one. In a small-cap pharma platform, consistent gross margin expansion and prescription-led growth usually matter more than a noisy net income line, and those drivers can support a re-rating before earnings revisions catch up.

Key Decisions for Investors

• Long KRKA on any post-print consolidation; target a 3-6 month re-rating as margin quality and capital returns become the focus rather than FX-distorted net income. Risk: renewed ruble weakness or pricing intervention compresses the thesis quickly.
• Pair trade: long KRKA / short a higher-FX-beta regional generic peer with weaker balance sheet and lower gross margin stability; this isolates the quality premium and reduces market directionality.
• Use a 1-2 quarter horizon to buy dips only if prescription growth remains double-digit; if that decelerates, the market will likely cut the multiple before full-year guidance matters.
• For more aggressive expression, buy medium-dated call spreads if listed liquidity is sufficient; the setup is asymmetric because buybacks and margin expansion can create steady upside while downside is cushioned by guidance reiteration.
• Avoid shorting on the reported net profit decline alone; that is the kind of accounting noise that can reverse next quarter and create a sharp squeeze if the market re-focuses on EBITDA and cash return.